HHS Targets Medicaid, Medicare Advantage Fraud
HHS watchdog prioritizes oversight into Medicare Advantage plans, highlighting settlements with Kaiser Permanente and Aetna
The Department of Health and Human Services is intensifying its efforts to combat fraud in Medicaid and Medicare Advantage programs, with a particular focus on rooting out "waste, fraud and abuse" in these systems, as noted by the HHS watchdog in a recent report featured on Healthcare Dive. This crackdown has already led to significant settlements, including a $556 million payment from Kaiser Permanente and a $117.7 million payment from Aetna, to resolve allegations of defrauding the Medicare Advantage program. The HHS Office of Inspector General has prioritized oversight into Medicare Advantage plans, highlighting the need for increased scrutiny in this area.
The issue of fraud in Medicaid is also being addressed through the implementation of work requirements, which states have until 2027 to begin enforcing, although several states have sued over these rules, arguing they could kick eligible people off coverage. However, as pointed out in an opinion piece on washingtonpost.com, Medicaid Fraud Control Units are not doing enough to control fraud, with indictments and convictions down despite a surge in funding, a topic further explored in the article Medicaid Fraud Control Units Ineffective. The lack of effective action by these units has raised concerns about the ability of the system to prevent and detect fraud.
In a recent crackdown on fraud, the HHS OIG recovered $5.56 billion and barred 1,200 individuals and entities from participating in federal healthcare programs, as reported on thehill.com. This included the sentencing of a healthcare software company CEO to 15 years in prison and ordering them to pay $452 million in restitution for a telemedicine and durable medical equipment fraud scheme. The report also cited hundreds of millions of dollars in restitution from the owners of wound graft companies and $674 million in settlements with Kaiser Permanente affiliates and Aetna over inflated Medicare Advantage billing. In another case, six individuals were charged with a $20 million healthcare fraud scheme, in which a pharmacy owner allegedly paid kickbacks to prescribers for selected high-reimbursement drugs and then submitted resulting claims to Medicare and Medicaid for medically unnecessary prescriptions.
The impact of fraud investigations can be significant, as seen in Minnesota, where the state paused Medicaid reimbursements to thousands of providers while implementing new anti-fraud measures, as discussed in the article SNAP Fraud Claims Met with Skepticism. The state's actions have put its care economy in crisis, with many providers facing financial difficulties due to the pause in payments. The situation in Minnesota highlights the need for effective and efficient anti-fraud measures that do not inadvertently harm legitimate providers. In contrast to these healthcare-related fraud schemes, Russian Nationals Indicted for $63M Cybercrime Scheme demonstrates the diverse range of fraud types being investigated and prosecuted.
As I reflect on the recent efforts by the Department of Health and Human Services to target Medicaid and Medicare Advantage fraud, I firmly believe that more needs to be done to prevent these scams. If nothing changes, the real winners will be the fraudulent providers and insurance companies who continue to exploit these vital programs for their own gain, leaving taxpayers and vulnerable beneficiaries to foot the bill. My thesis is that a more proactive and transparent approach is necessary to prevent fraud and protect these essential healthcare programs for those who truly need them.
Cross-reference independently — do not take our word for it.
Disclosure: NewsAnarchist uses AI-assisted reporting with web search. Always verify primary sources linked above.
This article is produced by NewsAnarchist's AI reporting system, not a human staff reporter. It's built from the primary source cited above (a regulator's enforcement action (SEC, FTC, DOJ), a company's own SEC filing, a court record, or the wire/trade-press reporting linked in the body) and reports what that source states, attributed to it — it is not a recommendation about any company's stock or products, and does not verify a company's disputed denial beyond what the record shows. Part of our Corporate Watchdog hub. Found an error? Tell us.